Clinical Trials — Currently Recruiting (Australia)

Ask your doctor whether you or your child may be eligible for any of these trials.

1. 1.

   A PHASE II PROSPECTIVE RANDOMIZED DOUBLE-MASKED CROSSOVER STUDY ASSESSING THE SAFETY & EFFICACY OF RHPRG4 (450 μG/ML RECOMBINANT HUMAN PROTEOGLYCAN 4) COMPARED TO VEHICLE FOR THE TREATMENT OF OCULAR GRAFT-VERSUS-HOST DISEASE (OGVHD)

   Recruiting — Phase 2 — Lubris Bio Pty Ltd

   https://clinicaltrials.gov/study/NCT07118254

2. 2.

   Phase 3 Extension Study to Evaluate Long-term Safety of Ianalumab in Participants With Systemic Lupus Erythematosus (SIRIUS-SLE Extension).

   Recruiting — Phase 3 — Novartis Pharmaceuticals

   https://clinicaltrials.gov/study/NCT06133972

3. 3.

   A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Metastatic Non-squamous NSCLC

   Recruiting — Phase 3 — AstraZeneca

   https://clinicaltrials.gov/study/NCT06627647

4. 4.

   A Study to Investigate the Safety, Tolerability, and Efficacy of AZD0120 in Adults With Refractory SLE

   Recruiting — Phase 1 — AstraZeneca

   https://clinicaltrials.gov/study/NCT06897930

5. 5.

   Phase IIIb Study of Ribociclib + ET in Early Breast Cancer

   Recruiting — Phase 3 — Novartis Pharmaceuticals

   https://clinicaltrials.gov/study/NCT05827081

6. 6.

   A PHASE II PROSPECTIVE RANDOMIZED DOUBLE-MASKED CONTROLLED STUDY ASSESSING THE SAFETY & EFFICACY OF RHPRG4 (450 µG/ML RECOMBINANT HUMAN PROTEOGLYCAN 4) COMPARED TO VEHICLE FOR THE TREATMENT OF SJÖGREN'S RELATED DRY EYE DISEASE

   Recruiting — Phase 2 — Lubris Bio Pty Ltd

   https://clinicaltrials.gov/study/NCT07118241

7. 7.

   Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7

   Recruiting — Phase 2 — Mirati Therapeutics Inc.

   https://clinicaltrials.gov/study/NCT04613596

8. 8.

   A Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC)

   Recruiting — Phase 1 — Hoffmann-La Roche

   https://clinicaltrials.gov/study/NCT04929223

9. 9.

   Study Evaluating Safety, Tolerability, PK/PD of Surovatamig in Adult RA or SLE Participants

   Recruiting — Phase 1 — AstraZeneca

   https://clinicaltrials.gov/study/NCT07201558

10. 10.

    Clinical Trial to Evaluate Safety, Tolerability, and Pharmacokinetics of SOF-SKN in Healthy Participants

    Recruiting — Early Phase 1 — Noxopharm Limited

    https://clinicaltrials.gov/study/NCT07072611

11. 11.

    A Phase III Study to Investigate the Efficacy and Safety of Anifrolumab in Adults With Chronic and/or Subacute Cutaneous Lupus Erythematosus

    Recruiting — Phase 3 — AstraZeneca

    https://clinicaltrials.gov/study/NCT06015737

12. 12.

    Validation of the Lupus Low Disease Activity State (LLDAS) in the Asia Pacific Region

    Recruiting — Monash University

    https://clinicaltrials.gov/study/NCT03138941

13. 13.

    A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence

    Recruiting — Phase 3 — Stemline Therapeutics, Inc.

    https://clinicaltrials.gov/study/NCT06492616

14. 14.

    A Phase 1/2a Study of DB-2304 in Healthy Adults and SLE Participants

    Recruiting — Phase 1 — DualityBio Inc.

    https://clinicaltrials.gov/study/NCT06625671

15. 15.

    A Study to Evaluate the Safety and Activity of SAR448501/DR-0201 in Patients With Autoimmune Rheumatic Diseases

    Recruiting — Phase 1 — Sanofi

    https://clinicaltrials.gov/study/NCT06647069

16. 16.

    A Phase 2 Master Protocol Assessing Inebilizumab and Blinatumomab in Autoimmune Diseases

    Recruiting — Phase 2 — Amgen

    https://clinicaltrials.gov/study/NCT06570798

17. 17.

    A Study of Rapcabtagene Autoleucel in Active, Refractory Systemic Lupus Erythematosus (SLE) or Lupus Nephritis (LN) Patients (AUTOGRAPH - SLE/LN)

    Recruiting — Phase 2 — Novartis Pharmaceuticals

    https://clinicaltrials.gov/study/NCT06581198

18. 18.

    A Study of CLN-978, a Subcutaneously Administered CD19-directed T Cell Engager, in Subjects With Systemic Lupus Erythematosus

    Recruiting — Phase 1 — Cullinan Therapeutics Inc.

    https://clinicaltrials.gov/study/NCT06613360

19. 19.

    A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)

    Recruiting — Phase 3 — AstraZeneca

    https://clinicaltrials.gov/study/NCT06692738

20. 20.

    A Study of Healthy Donor CD19-targeted Allogeneic CAR T Cells in Participants With Severe, Refractory Autoimmune Diseases

    Recruiting — Phase 1 — Juno Therapeutics, Inc., a Bristol-Myers Squibb Company

    https://clinicaltrials.gov/study/NCT07115745

21. 21.

    A Study of LY4298445 in Healthy Participants and Participants With Systemic Lupus Erythematosus (SLE) or Rheumatoid Arthritis (RA)

    Recruiting — Phase 1 — Eli Lilly and Company

    https://clinicaltrials.gov/study/NCT07276958

22. 22.

    Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus

    Recruiting — Phase 3 — AbbVie

    https://clinicaltrials.gov/study/NCT05843643

23. 23.

    ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer

    Recruiting — Phase 3 — BioNTech SE

    https://clinicaltrials.gov/study/NCT07173751